Hormone therapy in Brazilian postmenopausal women with chronic hepatitis C: a pilot study

被引：2
作者：
Padua, M. A. F. [1 ]
Fonseca, A. M. [1 ]
Deguti, M. M. [2 ]
Bagnoli, V. R. [1 ]
Farias, A. Q. [2 ]
Maciel, G. A. R. [1 ]
Soares, J. M., Jr. [1 ]
Carilho, F. J. [2 ]
Baracat, E. C. [1 ]
机构：
[1] Univ Sao Paulo, Fac Med, Dept Obstet & Gynecol, BR-04021051 Sao Paulo, Brazil
[2] Univ Sao Paulo, Fac Med, Dept Gastroenterol Hepatol, BR-04021051 Sao Paulo, Brazil
来源：
CLIMACTERIC | 2010年 / 13卷 / 02期
关键词：
MENOPAUSE; HEPATITIS C; LIVER FUNCTION; ESTROGEN THERAPY; ESTROGEN/ PROGESTIN THERAPY; LIVER FIBROSIS PROGRESSION; PRIMARY BILIARY-CIRRHOSIS; REPLACEMENT THERAPY; VENOUS THROMBOEMBOLISM; NATURAL-HISTORY; BENEFIT; IMPACT; MODEL; RISK;
D O I：
10.3109/13697130902952577
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Design Fifty out of 336 postmenopausal patients with chronic infection with the hepatitis C virus were selected. The non-inclusion criteria were other chronic or systemic liver diseases, severe vascular diseases, autoimmune diseases or malignant tumors. The patients were randomized into two groups: the HT group with 25 patients to be given transdermal hormone therapy (50 mu g estradiol plus 170 mu g norethisterone/day) and the control group with the other 25 patients (no medication). Hepatic tests (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase, total alkaline phosphatase, albumin, serum bilirubin) and hemostatic parameters (prothrombin time, factor V, fibrinogen) were evaluated at baseline and at 1, 4, 7 and 9 months of treatment. Results No significant changes in parameters were found in the comparison between the treated group and the controls, except for a decrease in total alkaline phosphatase (p = 0.002), presumably due to changes in bone remodelling. Conclusions There were no changes in liver function after a 9-month treatment with transdermal estradiol plus norethisterone in symptomatic postmenopausal patients with hepatitis C.
引用
收藏
页码：179 / 186
页数：8
相关论文
共 37 条
[1]   Hepatitis C virus entry: Molecular biology and clinical implications [J].
Barth, Heidi ;
Liang, T. Jake ;
Baumert, Thomas F. .
HEPATOLOGY, 2006, 44 (03) :527-535
[2]   Osteoporosis in primary biliary cirrhosis: A randomized trial of the efficacy and feasibility of estrogen/progestin [J].
Boone, Robert H. ;
Cheung, Angela M. ;
Girlan, Larisa M. ;
Heathcote, E. Jenny .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (06) :1103-1112
[3]   Are some progestins genotoxic liver carcinogens? [J].
Brambilla, G ;
Martelli, A .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2002, 512 (2-3) :155-163
[4]   Hormone therapy and venous thromboembolism among postmenopausal women -: Impact of the route of estrogen administration and progestogens:: The ESTHER study [J].
Canonico, Marianne ;
Oger, Emmanuel ;
Plu-Bureau, Genevieve ;
Conard, Jacqueline ;
Meyer, Guy ;
Levesque, Herve ;
Trillot, Nathalie ;
Barrellier, Marie-Therese ;
Wahl, Denis ;
Emmerich, Joseph ;
Scarabin, Pierre-Yves .
CIRCULATION, 2007, 115 (07) :840-845
[5]  
CHRISTIANSEN C, 1984, ACTA MED SCAND, V216, P11
[6]   Liver fibrosis in women with chronic hepatitis C:: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy [J].
Codes, Liana ;
Asselah, Tarik ;
Cazals-Hatem, Dominique ;
Tubach, Florence ;
Vidaud, Dominique ;
Parana, Raymundo ;
Bedossa, Pierre ;
Valla, Dominique ;
Marcellin, Patrick .
GUT, 2007, 56 (03) :390-395
[7]   Bone disorders in chronic liver disease [J].
Collier, Jane .
HEPATOLOGY, 2007, 46 (04) :1271-1278
[8]   Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure [J].
Di Martino, V ;
Lebray, P ;
Myers, RP ;
Pannier, E ;
Paradis, V ;
Charlotte, F ;
Moussalli, J ;
Thabut, D ;
Buffet, C ;
Poynard, T .
HEPATOLOGY, 2004, 40 (06) :1426-1433
[9]  
DUFOUR R, 2000, LAB GUIDELINES SCREE, V12
[10]   Predicting the fracture risk in 2008 [J].
Fardellone, Patrice .
JOINT BONE SPINE, 2008, 75 (06) :661-664
1234